tbuckley/cabot-search huggingface dataset:
Comparative Chromosomal Studies on Mammalian Cells in Culture. I. The HeLa Strain and Its Mutant Clonal Derivatives&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: Ernest H. Y. Chu, Norman H. Giles
Journal: JNCI Journal of the National Cancer Institute (1958)

Comparative Chromosomal Studies on Mammalian Cells in Culture. I. The HeLa Strain and Its Mutant Clonal Derivatives Get access Ernest H. Y. Chu, Ernest H. Y. Chu Department of Botany, Josiah Willard Gibbs Research Laboratories, Yale University, New Haven, Connecticut Search for other works by this author on: Oxford Academic PubMed Google Scholar Norman H. Giles Norman H. Giles Department of Botany, Josiah Willard Gibbs Research Laboratories, Yale University, New Haven, Connecticut Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 2, February 1958, Pages 383–401, https://doi.org/10.1093/jnci/20.2.383 Published: 01 February 1958 Article history Received: 31 July 1957 Published: 01 February 1958
Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma
Authors: Sina Burth, Philipp Kickingereder, Oliver Eidel, Diana Tichy, David Bonekamp, Lukas Weberling, Antje Wick, Sarah Löw, Anne Hertenstein, Martha Nowosielski, Heinz-Peter Schlemmer, Wolfgang Wick, Martin Bendszus, Alexander Radbruch
Journal: Neuro-Oncology (2016)

The purpose of this study was to determine the relevance of clinical data, apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) from dynamic susceptibility contrast (DSC) perfusion and the volume transfer constant (ktrans) from dynamic contrast-enhanced (DCE) perfusion for predicting overall survival (OS) and progression-free survival (PFS) in newly diagnosed treatment-naïve glioblastoma patients. Preoperative MR scans including standardized contrast-enhanced T1 (cT1), T2 - fluid-attenuated inversion recovery (FLAIR), ADC, DSC, and DCE of 125 patients with subsequent histopathologically confirmed glioblastoma were performed on a 3 Tesla MRI scanner. ADC, DSC, and DCE parameters were analyzed in semiautomatically segmented tumor volumes on contrast-enhanced (CE) cT1 and hyperintense signal changes on T2 FLAIR (ED). Univariate and multivariable Cox regression analyses including age, sex, extent of resection (EOR), and KPS were performed to assess the influence of each parameter on OS and PFS. Univariate Cox regression analysis demonstrated a significant association of age, KPS, and EOR with PFS and age, KPS, EOR, lower ADC, and higher rCBV with OS. Multivariable analysis showed independent significance of male sex, KPS, EOR, and increased rCBVCE for PFS, and age, sex, KPS, and EOR for OS. MRI parameters help to predict OS in a univariate Cox regression analysis, and increased rCBVCE is associated with shorter PFS in the multivariable model. In summary, however, our findings suggest that the relevance of MRI parameters is outperformed by clinical parameters in a multivariable analysis, which limits their prognostic value for survival prediction at the time of initial diagnosis.
Survival of Breast-Cancer Patients in Connecticut, 1935–42&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Sidney J. Cutler, Fred Ederer, Matthew H. Griswold, Richard A. Greenberg
Journal: JNCI Journal of the National Cancer Institute (1959)

We are presenting a detailed 20-year survival analysis by stage, age, calendar period of diagnosis, and treatment for cases of breast cancer diagnosed in the State of Connecticut between 1935 and 1954, and are including a review of statistical methodology in survival analysis. Observed survival is measured relative to expected survival in the general population. The 5-year relative survival rate for cases diagnosed during the first 10-year calendar period, 1935–44, was 50 percent. Mortality among the 5-year survivors was far in excess of that expected, based on general population experience. The 5-year relative survival rate for cases diagnosed during the second 10-year calendar period, 1945–54, was 56 percent. There was, however, no evidence of improvement in the 10-year survival rate. In general, there appeared to be little variation in the agespecific survival rates, except that among localized cases, women 75 to 84 years of age had a somewhat more favorable experience than women under 75, and among cases with regional spread, women under 35 had a lower survival rate than older women. The survival results in treatment of breast cancer in Connecticut are similar to those obtained in several well-known treatment centers.
Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis
Authors: Aaron M. Drucker, Annie R. Wang, Abrar A. Qureshi
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
AT-05VENO-OCCLUSIVE DISEASE (VOD) IS A NOTABLE SIDE EFFECT OF THERAPY IN INFANTS WITH RHABDOID TUMORS
Authors: Angela Seeringer, Gareth Veal, Petra Neumayer, Michael Fruehwald
Journal: Neuro-Oncology (2016)

Veno-occlusive disease (VOD) is a severe side effect of chemotherapy in very young patients.While the exact mechanisms are incompletely understood there is a strong association with certain cytostatics and combinations such as high dose chemotherapy (HDCT) or approaches including radiotherapy.Overall survival
Prevention of Cardiovascular Disease in Type 1 Diabetes
Authors: Camila Manrique-Acevedo, Irl B Hirsch, Robert H Eckel
Journal: New England Journal of Medicine (2024)

Patients with type 2 diabetes have a high risk of morbidity and premature mortality from cardiovascular disease. Epidemiological studies show that many of the risk factors are the same as in non-diabetic subjects. At present there are sufficient data in the literature to recommend prophylactic measures to be initiated in diabetic patients.We review major studies relevant for prophylactic measures against cardiovascular disease in patients with type 2 diabetes, and suggest Norwegian recommendations.All patients should be advised to adhere to a healthy life style including an appropriate diet, physical exercise and no smoking. Treatment of hyperglycaemia is primarily indicated in order to improve quality of life and reduce the risk of microvascular complications, as it still remains to be proven if glucose lowering therapy may protect against macrovascular disease. Pharmacological prophylactic therapy with acetylsalicylic acid, anti-hypertensive agents and lipid lowering drugs are indicated in high-risk patients.Several pharmacological and non-pharmacological interventions may protect type 2 diabetic patients from premature cardiovascular morbidity and mortality. Anti-hypertensive treatment may protect diabetic patients both from microvascular and macrovascular disease and premature death.
CR-12INTRACYSTIC INTERFERON-ALPHA IN PAEDIATRIC CRANIOPHARYNGIOMA PATIENTS: AN INTERNATIONAL MULTI-CENTRE ASSESSMENT ON BEHALF OF SIOP-E AND ISPN
Authors: J.P. Kilday, L. Massimi, M. Caldarelli, Y.Y. Lee, H.H. Chen, M.L. Yiang, J. Parkes, T. Naiker, M. van Veelen, E. Michiels, B. Pettorini, C. Mallucci, L. Meijer, C. Dorfer, T. Czech, M. Diezi, N. van Schouten, S. Holm, B. Gustavsson, M. Benesch, A. Hoffman, H. Muller, G. Escherich, J. Flitsch, S. Rutkowski, M. Grotzer, H.A. Spoudeas, M. Capra, R. Jimenez-Guerra, P. MacDonald, D.L. Johnston, R. Dvir, S. Constantini, M.F. Kuo, S.H. Yang, U. Bartels
Journal: Neuro-Oncology (2016)
Trypanosoma Cruzi in the Treatment of Mouse Tumors&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Theodore Hauschka, Leroy H. Saxe, Jr., Margaret Blair, N. Maxwell Tower, Jean Palmquist
Journal: JNCI Journal of the National Cancer Institute (1947)

Trypanosoma Cruzi in the Treatment of Mouse Tumors Get access Theodore Hauschka, Theodore Hauschka Institute for Cancer Research, Lankenau Hospital, Philadelphia Search for other works by this author on: Oxford Academic PubMed Google Scholar Leroy H. Saxe, Jr., Leroy H. Saxe, Jr. Institute for Cancer Research, Lankenau Hospital, Philadelphia Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret Blair, Margaret Blair Institute for Cancer Research, Lankenau Hospital, Philadelphia Search for other works by this author on: Oxford Academic PubMed Google Scholar N. Maxwell Tower, N. Maxwell Tower technical assistance Institute for Cancer Research, Lankenau Hospital, Philadelphia Search for other works by this author on: Oxford Academic PubMed Google Scholar Jean Palmquist Jean Palmquist Institute for Cancer Research, Lankenau Hospital, Philadelphia Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 4, February 1947, Pages 189–197, https://doi.org/10.1093/jnci/7.4.189 Published: 01 February 1947 Article history Received: 11 November 1946 Published: 01 February 1947
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Authors: Mattias Carlsten, Neha Korde, Ritesh Kotecha, Robert Reger, Simona Bor, Dickran Kazandjian, Ola Landgren, Richard W. Childs
Journal: Clinical Cancer Research (2016)

Immune checkpoint inhibitors have recently revolutionized cancer immunotherapy. On the basis of data showing KIR-ligand mismatched natural killer (NK) cells reduce the risk of leukemia and multiple myeloma relapse following allogeneic hematopoietic stem cell transplantation, investigators have developed a checkpoint inhibition antibody that blocks KIR on NK cells. Although in vitro studies suggest the KIR2D-specific antibody IPH2101 induces KIR-ligand mismatched tumor killing by NK cells, our single-arm phase II clinical trial in patients with smoldering multiple myeloma was prematurely terminated due to lack of clinical efficacy. This study aimed at unveiling the underlying mechanisms behind the lack of clinical efficacy.Treatment-naïve patients received an intravenous infusion of 1 mg/kg IPH2101 every other month for up to a year. Peripheral blood was collected at baseline and 24 hours after first infusion, followed by weekly samples for the first month and monthly samples thereafter. NK cell phenotype and function was analyzed using high-resolution flow cytometry.Unexpectedly, infusion of IPH2101 resulted in rapid reduction in both NK cell responsiveness and KIR2D expression on the NK cell surface. In vitro assays revealed KIR2D molecules are removed from the surface of IPH2101-treated NK cells by trogocytosis, with reductions in NK cell function directly correlating with loss of free KIR2D surface molecules. Although IPH2101 marginally augmented the antimyeloma cytotoxicity of remaining KIR2Ddull patient NK cells, the overall response was diminished by significant contraction and reduced function of KIR2D-expressing NK cells.These data raise concerns that the unexpected biological events reported in this study could compromise antibody-based strategies designed at augmenting NK cell tumor killing via checkpoint inhibition. Clin Cancer Res; 22(21); 5211-22. ©2016 AACRSee related commentary by Felices and Miller, p. 5161.
HG-113RADIOGRAPHIC FINDINGS IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SURVIVING ONE YEAR POST-DIAGNOSIS
Authors: Stephen Gilheeney, Sofia Haque, Kevin De Braganca, Yasmin Khakoo, David Lyden, Mark Souweidane
Journal: Neuro-Oncology (2016)

BACKGROUND: DIPG remains a terminal diagnosis.Many centers are reporting patients surviving greater than a year post-diagnosis as novel treatments and modalities are developed.METHODS: We identified all patients treated 2000 -present who met the following criteria: DIPG, alive one year after Overall survival
Treatment intensity differences in screen-detected and community-detected early stage breast cancer (ESBC).
Authors: Kenneth Jack Elder, Samuel Cooke, Dorothy Machalek, Allison Rose, Arlene Mou, John Paxton Collins, Carolyn Nickson, Allan Park, Bruce Mann
Journal: Journal of Clinical Oncology (2015)

1579 Background: The value of population based mammographic screening has been questioned by those who believe that the reduction in mortality from earlier diagnosis is outweighed by harms including overdiagnosis and overtreatment as well as harms of false positive recall for assessment. Intensity of treatment received is rarely mentioned in the debate. We hypothesised that screen-detected (SD) cancers would receive less extensive surgical treatment and less intense adjuvant therapies than community-detected (CD) cancers. If demonstrated, the extent of these differences would form an important component of the debate over the role of mammographic screening. Methods: Retrospective analysis of a consecutive cohort of female patients aged 40-75 and managed for ESBC between 2009-2013 within a large metropolitan Breast Service in Melbourne, Australia, diagnosed either via a population screening program (SD) or clinically referred to the Service (CD). Data on patient characteristics, symptoms, tumor characteristics and treatment recommendations were derived from hospital records. Results: 718 cases were identified. 28 had previous breast cancer and 7 metastatic disease, leaving 682 for analysis. 54% (367/682) were SD. Mean tumor size was smaller in the SD group (1.55cm vs 2.61cm, p < 0.0001) and nodal involvement was less common (24% vs 46%, p < 0.0001). Compared to CD cases, SD cases received less extensive surgery (mastectomy 14% vs 36% (p < 0.0001), axillary dissection 17% vs 40% (p < 0.0001)), less intensive adjuvant radiotherapy (radiotherapy after wide excision 93% vs 97% (p = 0.052), radiotherapy after mastectomy 34% vs 58% (p = 0.0039)). Endocrine therapy was more common in SD cancers reflecting differences in receptor status (93% vs 80% (p < 0.0001)), but chemotherapy was much less frequently used (32% vs 65% (p < 0.0001)). Conclusions: Women diagnosed with ESBC through a population based screening program are less likely to receive mastectomy and/or axillary dissection, less likely to be recommended to receive radiotherapy, and less likely to receive adjuvant chemotherapy. This difference in treatment intensity should be considered in the current debate surrounding mammographic screening.
Depression in patients with acute traumatic brain injury
Authors: J P Fedoroff, S E Starkstein, A W Forrester, F H Geisler, R E Jorge, S V Arndt, R G Robinson
Journal: American Journal of Psychiatry (1992)

This study was undertaken to examine patients with closed head injuries for the presence of depressive disorders.A consecutive series of 66 patients with closed head injuries but no significant spinal cord or other organ system injury were examined by means of a semistructured psychiatric interview. The Hamilton Rating Scale for Depression as well as scales measuring impairment in activities of daily living, intellectual functioning, and social functioning were administered. The patients' CT scans were also examined.Seventeen patients had major depression and two had minor depression. The presence of left dorsolateral frontal lesions and/or left basal ganglia lesions and, to a lesser extent, parietal-occipital and right hemisphere lesions was associated with an increased probability of developing major depression. Compared to the nondepressed group, the group with major depression had a higher frequency of previous psychiatric disorder and showed evidence of poorer social functioning.Major depression occurs in about one-quarter of patients after traumatic brain injury. This is the same frequency as in other major disorders such as stroke. Major depression appears to be provoked by one or more factors that include poor premorbid social functioning and previous psychiatric disorder or injury to certain critical brain locations.
TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)
Authors: Andreas Bühler, Clemens Wendtner, Michael Hallek, Thomas J. Kipps, Laura Rassenti, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, Matt Kalaycio, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, Stephan Stilgenbauer
Journal: Blood (2013)
Inhibition of Gross Leukemia Virus-Induced Plaque Formation in XC Cells by 3-Deazauridine2
Authors: William M. Shannon, R. Wallace Brockman, Louise Westbrook, Sue Shaddix, Frank M. Schabel
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Inhibition of Gross Leukemia Virus-Induced Plaque Formation in XC Cells by 3-Deazauridine Get access William M. Shannon, William M. Shannon Search for other works by this author on: Oxford Academic PubMed Google Scholar R. Wallace Brockman, R. Wallace Brockman Search for other works by this author on: Oxford Academic PubMed Google Scholar Louise Westbrook, Louise Westbrook Search for other works by this author on: Oxford Academic PubMed Google Scholar Sue Shaddix, Sue Shaddix Search for other works by this author on: Oxford Academic PubMed Google Scholar Frank M. Schabel, Jr. Frank M. Schabel, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 1, January 1974, Pages 199–205, https://doi.org/10.1093/jnci/52.1.199 Published: 01 January 1974 Article history Received: 13 July 1973 Accepted: 24 September 1973 Published: 01 January 1974
Gastritis: A Medical Dilemma
Authors: L BERLIN
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patterns of sex differences in negative symptoms and social functioning consistent with separate dimensions of schizophrenic psychopathology
Authors: R H Dworkin
Journal: American Journal of Psychiatry (1990)

In 220 schizophrenic twins, men had greater asociality-withdrawal and poorer premorbid social competence than women but there were no sex differences in symptoms, suggesting that negative symptoms and social functioning reflect different processes in the development and manifestation of schizophrenia and that they should be examined separately.
Histoplasmosis
Authors: Philip Daoust, Brian Schapiro
Journal: New England Journal of Medicine (1996)

Figure 1. A chest x-ray film (Panel A) in a 41-year-old man with human immunodeficiency virus infection who had a four-month history of fever, cough, and worsening dyspnea showed a diffuse, bilateral reticulonodular pattern. A blood smear (Panel B; Wright-Giemsa stain, ×1000) obtained on admission showed intracellular organisms in segmented neutrophils. These yeast-like organisms had a clear halo, suggesting a capsule, and were consistent with histoplasma. The diagnosis was confirmed by bronchoalveolar lavage (Panel C; Grocott's methenamine silver, ×1000), which showed small, budding yeast characteristic of histoplasma (1 to 4 μm in diameter). The patient was intubated and treated with . . .
Tricyclic-induced akathisia in patients taking conjugated estrogens
Authors: K R Krishnan, R D France, E H Ellinwood
Journal: American Journal of Psychiatry (1984)

Three patients taking conjugated estrogens developed akathisia induced by tricyclic antidepressants. The interaction between tricyclic antidepressants and conjugated estrogens could play a role in the development of akathisia.
Mechanism of Experimental Tumorigenesis. I. Epidermal Hyperplasia in Mouse Caused by Locally Applied Tumor Initiator and Dipole-Type Tumor Promotor<xref ref-type="fn" rid="FN1">2</xref>
Authors: Kai Setälä, Lauri Merenmies, Leo Stjernvall, Yrjö Aho, Paavo Kajanne
Journal: JNCI Journal of the National Cancer Institute (1959)

Laboratory-synthesized “membrane active agents,” Span 60 (sorbitan monostearate) and its ethylene oxide derivative, Tween 60 (polyoxyethylene sorbitan monostearate), and Tween 20 (polyoxyethylene sorbitan monolaurate), produced changes in skin on back of the mouse analogous to those caused by corresponding technical products. The degree of hyperplasia was correlated to the tumor-promoting property of the agent, or to its absence. The skin changes produced by a potent tumor promoter of Tween 60 type, which were analyzed histologically and histoquantitatively, differed from those caused by similarly applied carcinogens methylcholanthrene (MCA) and 9,10-dimethyl-1,2-benzanthracene (DMBA). A single application with MCA or DMBA immediately produced toxic alterations. Reparative hyperplasia set in only after the latter became quiescent. Continuous MCA or DMBA treatment caused cellular and nuclear atypia and severe disturbances in organization and differentiation, which increased progressively. Treatment with Tween 60 did not produce retrogressive alterations, but intense cell multiplication and high-degree hyperplasia commenced immediately. Continuous Tween 60 treatment caused neither cellular nor nuclear atypia, nor disturbances in organization; the amount of cells in differentiation increased significantly. Continuous treatment maintained the hyperplasia unchanged. After initial application of carcinogen, Tween 60 treatment evoked changes typical of carcinogens. Tween 20 (a weak tumor promoter) and Span 60 (an ineffectual compound) did not produce these alterations. The nature of tumor promotion after application of a pure dipole-type promoter is benign. Tumor promotion is not a phase of the carcinogenic process itself as these processes are contradictory. Tumor promotion is comparable to intense continuous reparative (“simple”) cell multiplication.